Treatment of ANCA-associated vasculitis [1]

JAMA

Volumn 298, Issue 23, 2007, Pages 2739-

  Santana, Alfredo N C ^a   Antunes, Telma ^a   Barbas, Carmen S V ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTROPHIL CYTOPLASMIC ANTIBODY; WARFARIN; ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; ANTICOAGULATION; DISEASE COURSE; DRUG INDICATION; HUMAN; LETTER; PRIORITY JOURNAL; VASCULITIS; VENOUS THROMBOEMBOLISM; WEGENER GRANULOMATOSIS; NOTE; THROMBOEMBOLISM;

ANTICOAGULANTS; HUMANS; THROMBOEMBOLISM; WARFARIN; WEGENER GRANULOMATOSIS;

EID: 37349049061     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.298.23.2739-a     Document Type: Letter

References (4)

1. Bosch X, Guilabert A, Espinosa G, Mirapeix E. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis: a systematic review. JAMA. 2007;298(6):655-669.
2. Merkel PA, Lo GH, Holbrook JT, et al; Wegener's Granulomatosis Etanercept Trial Research Group. High incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med. 2005;142(8):620-626.
3. Ridker PM, Goldhaber SZ, Danielson E, et al; PREVENT Investigators. Longterm, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003;348(15):1425-1434.
4. Kearon C, Ginsberg JS, Kovacs MJ, et al; Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003;349(7):631-639.